Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by westcoast1000on Feb 06, 2023 4:29pm
307 Views
Post# 35270309

Waiting leads to worry, facts can help....

Waiting leads to worry, facts can help....We are waiting, and will continue to wait for some unknown amount time, until ONCY has decided what it wants to do in the future.

On the frustrating Yahoo board, people complain that no one can know what is happening and the current silence is no proof we are in negotiations.

I looked at the web site, and back through the press releases for the last three years. Never in that period has there been such a prolonged black out on comments and complete lack of communication from the company as we have seen since December 8. That is almost two months, just after releasing the most significant and momentous results in the company's history, with the panc results, the seconf Fast Track and the highly encouraging AN early BC results.

That silence comes on top of ONCY showing results that should captivate all concerned with panc cancer treatment, and near immediate FDA response. Again, on the other board they complain that the FDA did not give them Accelerated Approval outright, so things must not be as optimistic or effective as the results implied. 

In my view the FDA would not give AA without an application or request from Roche and ONCY together. The tecentriq and chemo combo Roche markets is already approved. The FDA could not grant AA to adding in pela without a specific request, IMHO.

So the silence and the results of last November-December indicate to me that we are in the middle of negotiations.

The results of these negotiations are unknown. The exisitence of several potential bidders, and power of the panc results and the potential for the forthcoming BC results all suggests these negotiations will be going well. We all certainly hope that is the case.


<< Previous
Bullboard Posts
Next >>